Abstract
Background
This study evaluated the recurrence in patients with papillary thyroid cancer and an excellent response to initial therapy, comparing those with and without chronic lymphocytic thyroiditis.
Methods
This was a prospective study. Patients who met the following criteria were selected: diagnosis of papillary thyroid cancer; submitted to total thyroidectomy followed or not by ablation with 131I; and neck ultrasonography without abnormalities, nonstimulated thyroglobulina (Tg) ≤0.2 ng/ml, and undetectable antithyroglobulin antibodies (TgAb) 12–18 months after initial therapy. The patients were divided into two groups: group A, with chronic lymphocytic thyroiditis on histology; group B, without chronic lymphocytic thyroiditis on histology.
Results
Groups A and B were similar in terms of sex and age of the patients, characteristics of the tumor, tumor-node-metastase stage and risk category. The time of follow-up ranged from 24 to 120 months (median 66 months). During follow-up, 5 patients of group A (2.6 %) and 9 patients of group B (2 %) developed recurrence (p = 0.77). Patients with chronic lymphocytic thyroiditis were more likely to progress to persistently borderline TgAb. No patient had positive TgAb (above the reference value) during follow-up. Recurrences occurred in 12/588 patients (2 %) with undetectable TgAb in all measurements, in 1/32 (3.1 %) with detectable TgAb on some occasion but that returned to undetectable spontaneously, and in 1/13 (7.7 %) with persistently borderline TgAb. These rates did not differ significantly (p = 0.25).
Conclusion
The results of the present study showed the absence of an association between chronic lymphocytic thyroiditis and recurrence risk at least in patients with an excellent response to initial therapy.
Similar content being viewed by others
References
K. Kashima, S. Yokoyama, S. Noguchi, N. Murakami, H. Yamashita, S. Watanabe, S. Uchino, M. Toda, A. Sasaki, T. Daa, I. Nakayama, I. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 8, 197–202 (1998)
K.C. Loh, F.S. Greenspan, F. Dong, T.R. Miller, P.P. Yeo, Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 84, 458–463 (1999)
E. Kebebew, P.A. Treseler, P.H. Ituarte, O.H. Clark, Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World. J. Surg. 25, 632–637 (2001)
E.Y. Kim, W.G. Kim, W.B. Kim, T.Y. Kim, J.M. Kim, J.S. Ryu, S.J. Hong, G. Gong, Y.K. Shong, Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin. Endocrinol. (Oxf) 71, 581–586 (2009)
B.Y. Huang, C. Hseuh, T.C. Chao, K.J. Lin, J.D. Lin, Well-differentiated thyroid carcinoma with concomitant Hashimoto’s thyroiditis present with less aggressive clinical stage and low recurrence. Endocr. Pathol. 22, 144–149 (2011)
J.S. Jeong, H.K. Kim, C.R. Lee, S. Park, J.H. Park, S.W. Kang, J.J. Jeong, K.H. Nam, W.Y. Chung, C.S. Park, Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: clinical manifestation and prognostic outcome. J. Korean Med. Sci. 27, 883–889 (2012)
R.M. Tuttle, H. Tala, J. Shah, R. Leboeuf, R. Ghossein, M. Gonen, M. Brokhin, G. Omry, J.A. Fagin, A. Shaha, Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20, 1341–1349 (2010)
M.G. Castagna, F. Maino, C. Cipri, V. Belardini, A. Theodoropoulou, G. Cevenini, F. Pacini, Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur. J. Endocrinol. 165, 441–446 (2011)
F. Vaisman, D. Momesso, D.A. Bulzico, C.H. Pessoa, F. Dias, R. Corbo, M. Vaisman, R.M. Tuttle, Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol. (Oxf). 77, 132–138 (2012)
M.J. Jeon, W.G. Kim, W.R. Park, J.M. Han, T.Y. Kim, D.E. Song, K.W. Chung, J.S. Ryu, S.J. Hong, Y.K. Shong, W.B. Kim, Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 170, 23–30 (2013)
F. Pitoia, F. Bueno, C. Urciuoli, E. Abelleira, G. Cross, R.M. Tuttle, Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. Thyroid 23, 1401–1407 (2013)
R.S. Scheffel, A.B. Zanella, D. Antunes, J.M. Dora, A.L. Maia, Low recurrence rates in a cohort of differentiated thyroid carcinoma patients: a referral center experience. Thyroid 25, 883–889 (2015)
L. Giovanella, G. Treglia, R. Sadeghi, P. Trimboli, L. Ceriani, F.A. Verburg FA., Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 440–447 (2014)
M. Brassard, I. Borget, A. Edet-Sanson, A.L. Giraudet, O. Mundler, M. Toubeau, F. Bonichon, F. Borson-Chazot, L. Leenhardt, C. Schvartz, C. Dejax, I. Brenot-Rossi, M.E. Toubert, M. Torlontano, E. Benhamou, M. Schlumberger, Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J. Clin. Endocrinol. Metab. 96, 1352–1359 (2011)
B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016)
P.W. Rosario, G.C. Penna, M.R. Calsolari, Noninvasive encapsulated follicular variant of papillary thyroid carcinoma: is lobectomy sufficient for tumours ≥1 cm? Clin Endocrinol. (Oxf) 81, 630–632 (2014)
P.W. Rosario, S. de Faria, L. Bicalho, M.F. Alves, M.A. Borges, S. Purisch, E.L. Padrão, L.L. Rezende, A.L. Barroso, Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J. Ultrasound. Med. 24, 1385–1389 (2005)
P.W. Rosario, W.C. Tavares, M.A. Borges, J.B. Santos, M.R. Calsolari, Ultrasonographic differentiation of cervical lymph nodes in patients with papillary thyroid carcinoma after thyroidectomy and radioiodine ablation: a prospective study. Endocr. Pract. 20, 293–298 (2014)
C. Durante, T. Montesano, M. Torlontano, M. Attard, F. Monzani, S. Tumino, G. Costante, D. Meringolo, R. Bruno, F. Trulli, M. Massa, A. Maniglia, R. D’Apollo, L. Giacomelli, G. Ronga, S. Filetti, Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J. Clin. Endocrinol. Metab. 98, 636–642 (2013)
F. Latrofa, D. Ricci, L. Montanelli, R. Rocchi, P. Piaggi, E. Sisti, L. Grasso, F. Basolo, C. Ugolini, A. Pinchera, P. Vitti, Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin. J. Clin. Endocrinol. Metab. 97, 2380–2387 (2012)
J.K. Chung, Y.J. Park, T.Y. Kim, Y. So, S.K. Kim, D.J. Park, D.S. Lee, M.C. Lee, B.Y. Cho, Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 57, 215–221 (2002)
W.G. Kim, J.H. Yoon, W.B. Kim, T.Y. Kim, E.Y. Kim, J.M. Kim, J.S. Ryu, G. Gong, S.J. Hong, Y.K. Shong, Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 93, 4683–4689 (2008)
C.J. Hsieh, P.W. Wang, Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma. Thyroid 24, 488–493 (2014)
C. Durante, S. Tognini, T. Montesano, F. Orlandi, M. Torlontano, E. Puxeddu, M. Attard, G. Costante, S. Tumino, D. Meringolo, R. Bruno, F. Trulli, M. Toteda, A. Redler, G. Ronga, S. Filetti, F. Monzani, Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. Thyroid 24, 1139–1145 (2014)
P.W. Rosario, M. Carvalho, G.F. Mourão, M.R. Calsolari, Comparison of antithyroglobulin antibody concentrations before and after ablation with 131I as a predictor of structural disease in differentiated thyroid carcinoma patients with undetectable basal thyroglobulin and negative neck ultrasonography. Thyroid 26, 525–531 (2016)
L.L. Cunha, M.A. Marcello, S. Nonogaki, E.C. Morari, F.A. Soares, J. Vassallo, L.S. Ward, CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer. Clin. Endocrinol. (Oxf) 83, 246–253 (2015)
J.H. Lee, Y. Kim, J.W. Choi, Y.S. Kim, The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur. J. Endocrinol. 168, 343–349 (2013)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Informed consent
The study was approved by the local Research Ethics Committee and the subjects gave written informed consent.
Rights and permissions
About this article
Cite this article
Carvalho, M.S., Rosario, P.W., Mourão, G.F. et al. Chronic lymphocytic thyroiditis does not influence the risk of recurrence in patients with papillary thyroid carcinoma and excellent response to initial therapy. Endocrine 55, 954–958 (2017). https://doi.org/10.1007/s12020-016-1185-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-016-1185-1